Stem definition | Drug id | CAS RN |
---|---|---|
1920 | 54-11-5 |
Dose | Unit | Route |
---|---|---|
30 | mg | Chewing gum |
60 | mg | Inhal |
30 | mg | N |
30 | mg | SL |
14 | mg | TD |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 16.70 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 3.52 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 30 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 2.60 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 18 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.95 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
Nov. 7, 1991 | FDA | SANOFI AVENTIS US |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nicotine dependence | 560.73 | 13.57 | 106 | 15167 | 549 | 50589302 |
Macular degeneration | 422.22 | 13.57 | 160 | 15113 | 14228 | 50575623 |
Drug withdrawal syndrome neonatal | 283.83 | 13.57 | 73 | 15200 | 1768 | 50588083 |
Drug dependence | 255.68 | 13.57 | 123 | 15150 | 19636 | 50570215 |
Incorrect product administration duration | 211.58 | 13.57 | 86 | 15187 | 9189 | 50580662 |
Premature delivery | 206.55 | 13.57 | 113 | 15160 | 23550 | 50566301 |
Foetal exposure during pregnancy | 204.49 | 13.57 | 118 | 15155 | 27241 | 50562610 |
Product adhesion issue | 185.59 | 13.57 | 64 | 15209 | 4328 | 50585523 |
Overdose | 169.18 | 13.57 | 178 | 15095 | 99549 | 50490302 |
Maternal exposure during pregnancy | 127.79 | 13.57 | 196 | 15077 | 159582 | 50430269 |
Myocardial stunning | 100.71 | 13.57 | 20 | 15253 | 139 | 50589712 |
Intentional product misuse | 85.57 | 13.57 | 87 | 15186 | 46647 | 50543204 |
Application site erythema | 83.09 | 13.57 | 36 | 15237 | 4502 | 50585349 |
Jaundice neonatal | 81.75 | 13.57 | 23 | 15250 | 788 | 50589063 |
Accidental overdose | 80.59 | 13.57 | 58 | 15215 | 19475 | 50570376 |
Dependence | 74.10 | 13.57 | 26 | 15247 | 1849 | 50588002 |
Application site pruritus | 72.71 | 13.57 | 31 | 15242 | 3728 | 50586123 |
Drug abuse | 69.57 | 13.57 | 88 | 15185 | 59758 | 50530093 |
Necrosis ischaemic | 68.62 | 13.57 | 20 | 15253 | 779 | 50589072 |
Product quality issue | 66.85 | 13.57 | 63 | 15210 | 30795 | 50559056 |
Rhesus incompatibility | 66.69 | 13.57 | 13 | 15260 | 81 | 50589770 |
Poor feeding infant | 64.83 | 13.57 | 15 | 15258 | 229 | 50589622 |
Premature baby | 63.46 | 13.57 | 49 | 15224 | 18288 | 50571563 |
Exposure during pregnancy | 63.12 | 13.57 | 123 | 15150 | 120892 | 50468959 |
Pneumonia streptococcal | 58.33 | 13.57 | 21 | 15252 | 1610 | 50588241 |
Oligohydramnios | 54.43 | 13.57 | 29 | 15244 | 5721 | 50584130 |
Beta haemolytic streptococcal infection | 52.35 | 13.57 | 20 | 15253 | 1810 | 50588041 |
Maternal exposure during breast feeding | 50.53 | 13.57 | 23 | 15250 | 3231 | 50586620 |
Rib deformity | 47.91 | 13.57 | 11 | 15262 | 162 | 50589689 |
Tobacco abuse | 47.06 | 13.57 | 14 | 15259 | 586 | 50589265 |
Chronic obstructive pulmonary disease | 46.07 | 13.57 | 68 | 15205 | 53367 | 50536484 |
Low birth weight baby | 45.59 | 13.57 | 26 | 15247 | 5855 | 50583996 |
Exposure via breast milk | 40.42 | 13.57 | 16 | 15257 | 1592 | 50588259 |
Treatment noncompliance | 39.32 | 13.57 | 47 | 15226 | 30103 | 50559748 |
Rheumatoid arthritis | 39.06 | 13.57 | 7 | 15266 | 202543 | 50387308 |
Application site rash | 37.67 | 13.57 | 17 | 15256 | 2340 | 50587511 |
Application site reaction | 37.14 | 13.57 | 12 | 15261 | 662 | 50589189 |
Congenital tricuspid valve incompetence | 36.51 | 13.57 | 8 | 15265 | 94 | 50589757 |
Anxiety | 35.47 | 13.57 | 126 | 15147 | 177480 | 50412371 |
Congenital pulmonary hypertension | 34.27 | 13.57 | 7 | 15266 | 57 | 50589794 |
Alopecia | 32.07 | 13.57 | 17 | 15256 | 245030 | 50344821 |
Arthropathy | 31.44 | 13.57 | 5 | 15268 | 157901 | 50431950 |
Substance abuse | 31.34 | 13.57 | 18 | 15255 | 4106 | 50585745 |
Reversible cerebral vasoconstriction syndrome | 29.85 | 13.57 | 14 | 15259 | 2105 | 50587746 |
Premature separation of placenta | 29.70 | 13.57 | 13 | 15260 | 1665 | 50588186 |
Developmental hip dysplasia | 29.52 | 13.57 | 12 | 15261 | 1279 | 50588572 |
Reversible airways obstruction | 28.65 | 13.57 | 11 | 15262 | 1009 | 50588842 |
Nasal obstruction | 28.48 | 13.57 | 11 | 15262 | 1025 | 50588826 |
Caesarean section | 28.39 | 13.57 | 29 | 15244 | 15610 | 50574241 |
Toxicity to various agents | 28.30 | 13.57 | 133 | 15140 | 212366 | 50377485 |
Agitation neonatal | 27.90 | 13.57 | 9 | 15264 | 494 | 50589357 |
Maternal drugs affecting foetus | 27.89 | 13.57 | 18 | 15255 | 5059 | 50584792 |
Dysmetropsia | 27.04 | 13.57 | 6 | 15267 | 75 | 50589776 |
Application site irritation | 26.93 | 13.57 | 12 | 15261 | 1603 | 50588248 |
Throat clearing | 26.93 | 13.57 | 11 | 15262 | 1187 | 50588664 |
Loss of proprioception | 26.73 | 13.57 | 8 | 15265 | 342 | 50589509 |
Joint swelling | 26.66 | 13.57 | 21 | 15252 | 245265 | 50344586 |
Axonal neuropathy | 26.08 | 13.57 | 10 | 15263 | 914 | 50588937 |
Fatigue | 25.27 | 13.57 | 119 | 15154 | 707482 | 49882369 |
Xanthogranuloma | 24.76 | 13.57 | 4 | 15269 | 6 | 50589845 |
Systemic lupus erythematosus | 24.75 | 13.57 | 6 | 15267 | 140616 | 50449235 |
Off label use | 24.00 | 13.57 | 69 | 15204 | 474357 | 50115494 |
Treatment failure | 23.97 | 13.57 | 6 | 15267 | 137631 | 50452220 |
Application site swelling | 23.95 | 13.57 | 8 | 15265 | 490 | 50589361 |
Abnormal dreams | 23.93 | 13.57 | 21 | 15252 | 9356 | 50580495 |
Therapeutic product effect decreased | 23.56 | 13.57 | 6 | 15267 | 136044 | 50453807 |
Drug intolerance | 23.50 | 13.57 | 19 | 15254 | 219085 | 50370766 |
Symphysiolysis | 23.14 | 13.57 | 4 | 15269 | 11 | 50589840 |
Arthralgia | 22.77 | 13.57 | 63 | 15210 | 438639 | 50151212 |
Application site dermatitis | 22.32 | 13.57 | 6 | 15267 | 173 | 50589678 |
Premature labour | 22.15 | 13.57 | 22 | 15251 | 11454 | 50578397 |
Abortion induced | 22.01 | 13.57 | 20 | 15253 | 9324 | 50580527 |
Irritability | 21.42 | 13.57 | 34 | 15239 | 28392 | 50561459 |
Pain | 20.25 | 13.57 | 98 | 15175 | 578805 | 50011046 |
Respiratory failure | 20.19 | 13.57 | 67 | 15206 | 91114 | 50498737 |
Sneezing | 20.15 | 13.57 | 23 | 15250 | 14021 | 50575830 |
Contraindicated product administered | 19.97 | 13.57 | 10 | 15263 | 148948 | 50440903 |
Cardiac death | 19.89 | 13.57 | 7 | 15266 | 502 | 50589349 |
False positive investigation result | 19.68 | 13.57 | 7 | 15266 | 518 | 50589333 |
Application site vesicles | 19.23 | 13.57 | 9 | 15264 | 1346 | 50588505 |
Sputum purulent | 18.81 | 13.57 | 8 | 15265 | 955 | 50588896 |
Drug screen positive | 18.53 | 13.57 | 12 | 15261 | 3390 | 50586461 |
Pre-eclampsia | 18.52 | 13.57 | 17 | 15256 | 8027 | 50581824 |
Suicidal ideation | 18.34 | 13.57 | 47 | 15226 | 55338 | 50534513 |
Oophoritis | 18.18 | 13.57 | 4 | 15269 | 48 | 50589803 |
Prinzmetal angina | 17.67 | 13.57 | 7 | 15266 | 698 | 50589153 |
Full blood count abnormal | 17.66 | 13.57 | 28 | 15245 | 23360 | 50566491 |
Nightmare | 17.64 | 13.57 | 23 | 15250 | 16063 | 50573788 |
Application site pain | 17.33 | 13.57 | 12 | 15261 | 3786 | 50586065 |
Infection | 17.32 | 13.57 | 16 | 15257 | 172938 | 50416913 |
Megacolon | 17.27 | 13.57 | 9 | 15264 | 1697 | 50588154 |
Secondary immunodeficiency | 17.20 | 13.57 | 8 | 15265 | 1180 | 50588671 |
Application site burn | 17.02 | 13.57 | 7 | 15266 | 769 | 50589082 |
Selective eating disorder | 16.66 | 13.57 | 9 | 15264 | 1823 | 50588028 |
Loss of consciousness | 16.66 | 13.57 | 69 | 15204 | 104284 | 50485567 |
Application site scar | 16.46 | 13.57 | 5 | 15268 | 225 | 50589626 |
Withdrawal syndrome | 16.04 | 13.57 | 23 | 15250 | 17567 | 50572284 |
Tobacco poisoning | 15.78 | 13.57 | 4 | 15269 | 91 | 50589760 |
Completed suicide | 15.70 | 13.57 | 80 | 15193 | 131809 | 50458042 |
Drug abuser | 15.47 | 13.57 | 10 | 15263 | 2818 | 50587033 |
Swelling | 15.38 | 13.57 | 23 | 15250 | 200849 | 50389002 |
Musculoskeletal stiffness | 15.25 | 13.57 | 10 | 15263 | 128471 | 50461380 |
Foetal growth restriction | 15.25 | 13.57 | 14 | 15259 | 6613 | 50583238 |
Glossodynia | 15.12 | 13.57 | 8 | 15265 | 115561 | 50474290 |
Schizoaffective disorder | 15.10 | 13.57 | 9 | 15264 | 2197 | 50587654 |
Patent ductus arteriosus | 14.97 | 13.57 | 11 | 15262 | 3809 | 50586042 |
Discomfort | 14.94 | 13.57 | 7 | 15266 | 108373 | 50481478 |
Chest X-ray abnormal | 14.80 | 13.57 | 11 | 15262 | 3874 | 50585977 |
Hepatitis C | 14.57 | 13.57 | 12 | 15261 | 4905 | 50584946 |
Tobacco interaction | 14.52 | 13.57 | 3 | 15270 | 26 | 50589825 |
Rhinitis | 14.36 | 13.57 | 15 | 15258 | 8286 | 50581565 |
Wound | 14.33 | 13.57 | 7 | 15266 | 105787 | 50484064 |
Nervousness | 14.25 | 13.57 | 28 | 15245 | 27623 | 50562228 |
Plethysmography | 13.87 | 13.57 | 3 | 15270 | 33 | 50589818 |
Foetal distress syndrome | 13.85 | 13.57 | 7 | 15266 | 1238 | 50588613 |
Abdominal discomfort | 13.75 | 13.57 | 31 | 15242 | 231610 | 50358241 |
Drug withdrawal syndrome | 13.66 | 13.57 | 26 | 15247 | 25055 | 50564796 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nicotine dependence | 368.21 | 13.62 | 75 | 12355 | 412 | 29561685 |
Drug withdrawal syndrome neonatal | 293.06 | 13.62 | 92 | 12338 | 3303 | 29558794 |
Drug dependence | 273.37 | 13.62 | 146 | 12284 | 20835 | 29541262 |
Incorrect product administration duration | 222.44 | 13.62 | 78 | 12352 | 3963 | 29558134 |
Foetal exposure during pregnancy | 199.52 | 13.62 | 142 | 12288 | 33725 | 29528372 |
Intentional product misuse | 160.91 | 13.62 | 126 | 12304 | 34535 | 29527562 |
Accidental overdose | 135.12 | 13.62 | 87 | 12343 | 17506 | 29544591 |
Overdose | 132.09 | 13.62 | 165 | 12265 | 79654 | 29482443 |
Product adhesion issue | 119.18 | 13.62 | 38 | 12392 | 1433 | 29560664 |
Maternal exposure during breast feeding | 102.57 | 13.62 | 34 | 12396 | 1452 | 29560645 |
Premature baby | 96.02 | 13.62 | 70 | 12360 | 17210 | 29544887 |
Dependence | 76.74 | 13.62 | 25 | 12405 | 1010 | 29561087 |
Low birth weight baby | 74.92 | 13.62 | 42 | 12388 | 6566 | 29555531 |
Alcohol abuse | 64.46 | 13.62 | 33 | 12397 | 4300 | 29557797 |
Jaundice neonatal | 64.36 | 13.62 | 23 | 12407 | 1233 | 29560864 |
Foetal disorder | 62.49 | 13.62 | 20 | 12410 | 763 | 29561334 |
Exposure via breast milk | 57.43 | 13.62 | 23 | 12407 | 1689 | 29560408 |
Neutropenia neonatal | 53.33 | 13.62 | 17 | 12413 | 640 | 29561457 |
Toxicity to various agents | 52.33 | 13.62 | 176 | 12254 | 173485 | 29388612 |
Tobacco poisoning | 52.16 | 13.62 | 9 | 12421 | 15 | 29562082 |
Drug screen positive | 48.15 | 13.62 | 26 | 12404 | 3775 | 29558322 |
Drug abuser | 47.99 | 13.62 | 26 | 12404 | 3801 | 29558296 |
Poor feeding infant | 46.34 | 13.62 | 14 | 12416 | 440 | 29561657 |
Tremor neonatal | 44.70 | 13.62 | 13 | 12417 | 357 | 29561740 |
Alcohol interaction | 44.35 | 13.62 | 22 | 12408 | 2681 | 29559416 |
Body temperature abnormal | 36.87 | 13.62 | 12 | 12418 | 483 | 29561614 |
Breech presentation | 36.02 | 13.62 | 9 | 12421 | 136 | 29561961 |
Foetal distress syndrome | 35.52 | 13.62 | 14 | 12416 | 985 | 29561112 |
Application site pruritus | 35.28 | 13.62 | 15 | 12415 | 1282 | 29560815 |
Schizophrenia | 35.10 | 13.62 | 26 | 12404 | 6539 | 29555558 |
Agitation neonatal | 34.77 | 13.62 | 14 | 12416 | 1042 | 29561055 |
Substance abuse | 34.33 | 13.62 | 26 | 12404 | 6761 | 29555336 |
Tobacco abuse | 31.18 | 13.62 | 10 | 12420 | 384 | 29561713 |
Drug use disorder | 28.93 | 13.62 | 18 | 12412 | 3404 | 29558693 |
Withdrawal syndrome | 28.92 | 13.62 | 29 | 12401 | 10963 | 29551134 |
Application site erythema | 28.39 | 13.62 | 15 | 12415 | 2084 | 29560013 |
Laryngeal dysplasia | 27.10 | 13.62 | 4 | 12426 | 0 | 29562097 |
Finnegan score increased | 26.95 | 13.62 | 5 | 12425 | 15 | 29562082 |
Drug abuse | 26.71 | 13.62 | 84 | 12346 | 79799 | 29482298 |
Application site reaction | 26.69 | 13.62 | 9 | 12421 | 405 | 29561692 |
Product quality issue | 26.42 | 13.62 | 33 | 12397 | 15862 | 29546235 |
Off label use | 25.85 | 13.62 | 55 | 12375 | 300745 | 29261352 |
Regurgitation | 25.56 | 13.62 | 12 | 12418 | 1295 | 29560802 |
Infant irritability | 25.27 | 13.62 | 5 | 12425 | 23 | 29562074 |
Venolymphatic malformation | 25.10 | 13.62 | 5 | 12425 | 24 | 29562073 |
Drug withdrawal syndrome | 24.71 | 13.62 | 34 | 12396 | 17950 | 29544147 |
Tobacco user | 24.67 | 13.62 | 9 | 12421 | 512 | 29561585 |
Tachycardia | 23.16 | 13.62 | 75 | 12355 | 72335 | 29489762 |
Oropharyngeal discomfort | 23.03 | 13.62 | 14 | 12416 | 2542 | 29559555 |
Treatment noncompliance | 22.26 | 13.62 | 38 | 12392 | 24189 | 29537908 |
Vitamin B12 deficiency | 22.23 | 13.62 | 15 | 12415 | 3256 | 29558841 |
Application site rash | 21.32 | 13.62 | 9 | 12421 | 755 | 29561342 |
Renal hypoplasia | 20.93 | 13.62 | 5 | 12425 | 62 | 29562035 |
Diarrhoea | 20.23 | 13.62 | 72 | 12358 | 332626 | 29229471 |
Infective exacerbation of chronic obstructive airways disease | 20.10 | 13.62 | 11 | 12419 | 1639 | 29560458 |
Acne infantile | 19.92 | 13.62 | 5 | 12425 | 77 | 29562020 |
Application site scar | 19.47 | 13.62 | 4 | 12426 | 23 | 29562074 |
Floppy infant | 18.33 | 13.62 | 5 | 12425 | 108 | 29561989 |
Renal impairment | 17.78 | 13.62 | 6 | 12424 | 81327 | 29480770 |
Pulmonary valve stenosis congenital | 17.31 | 13.62 | 5 | 12425 | 134 | 29561963 |
Application site vesicles | 17.21 | 13.62 | 7 | 12423 | 535 | 29561562 |
Euphoric mood | 17.05 | 13.62 | 15 | 12415 | 4810 | 29557287 |
Weight decrease neonatal | 16.69 | 13.62 | 6 | 12424 | 327 | 29561770 |
Breathing-related sleep disorder | 16.31 | 13.62 | 5 | 12425 | 165 | 29561932 |
Myoclonic epilepsy | 16.19 | 13.62 | 8 | 12422 | 967 | 29561130 |
Insomnia | 16.17 | 13.62 | 77 | 12353 | 88684 | 29473413 |
Emphysema | 16.03 | 13.62 | 19 | 12411 | 8652 | 29553445 |
Neonatal hypoxia | 15.87 | 13.62 | 6 | 12424 | 377 | 29561720 |
Palpitations | 15.52 | 13.62 | 39 | 12391 | 32565 | 29529532 |
Anxiety | 15.51 | 13.62 | 74 | 12356 | 85291 | 29476806 |
Antipsychotic drug level increased | 15.47 | 13.62 | 12 | 12418 | 3231 | 29558866 |
Necrotising ulcerative gingivostomatitis | 15.41 | 13.62 | 4 | 12426 | 71 | 29562026 |
Application site urticaria | 15.35 | 13.62 | 4 | 12426 | 72 | 29562025 |
Hypersensitivity | 15.31 | 13.62 | 53 | 12377 | 52850 | 29509247 |
Eructation | 15.26 | 13.62 | 13 | 12417 | 3993 | 29558104 |
Application site discolouration | 14.96 | 13.62 | 5 | 12425 | 219 | 29561878 |
Nightmare | 14.81 | 13.62 | 21 | 12409 | 11396 | 29550701 |
Drug tolerance increased | 14.77 | 13.62 | 6 | 12424 | 457 | 29561640 |
Application site pain | 14.62 | 13.62 | 9 | 12421 | 1670 | 29560427 |
Neonatal disorder | 14.56 | 13.62 | 7 | 12423 | 796 | 29561301 |
Death | 14.24 | 13.62 | 85 | 12345 | 341999 | 29220098 |
Potentiating drug interaction | 14.11 | 13.62 | 13 | 12417 | 4425 | 29557672 |
Knee deformity | 13.66 | 13.62 | 6 | 12424 | 555 | 29561542 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Nicotine dependence | 570.18 | 12.12 | 113 | 21193 | 701 | 64476725 |
Drug dependence | 481.29 | 12.12 | 230 | 21076 | 33082 | 64444344 |
Incorrect product administration duration | 343.15 | 12.12 | 127 | 21179 | 9631 | 64467795 |
Overdose | 244.90 | 12.12 | 282 | 21024 | 159284 | 64318142 |
Accidental overdose | 221.45 | 12.12 | 138 | 21168 | 33419 | 64444007 |
Intentional product misuse | 155.45 | 12.12 | 153 | 21153 | 72142 | 64405284 |
Application site erythema | 98.19 | 12.12 | 42 | 21264 | 4647 | 64472779 |
Myocardial stunning | 95.57 | 12.12 | 20 | 21286 | 168 | 64477258 |
Application site pruritus | 92.02 | 12.12 | 37 | 21269 | 3502 | 64473924 |
Product adhesion issue | 86.39 | 12.12 | 32 | 21274 | 2427 | 64474999 |
Drug abuse | 78.89 | 12.12 | 150 | 21156 | 132224 | 64345202 |
Toxicity to various agents | 75.20 | 12.12 | 277 | 21029 | 363236 | 64114190 |
Alcohol abuse | 71.49 | 12.12 | 34 | 21272 | 4818 | 64472608 |
Substance abuse | 65.80 | 12.12 | 40 | 21266 | 9252 | 64468174 |
Necrosis ischaemic | 62.75 | 12.12 | 20 | 21286 | 963 | 64476463 |
Drug abuser | 59.99 | 12.12 | 32 | 21274 | 5776 | 64471650 |
Beta haemolytic streptococcal infection | 53.42 | 12.12 | 21 | 21285 | 1873 | 64475553 |
Product quality issue | 53.00 | 12.12 | 57 | 21249 | 29742 | 64447684 |
Pneumonia streptococcal | 52.11 | 12.12 | 22 | 21284 | 2356 | 64475070 |
Application site reaction | 51.69 | 12.12 | 16 | 21290 | 699 | 64476727 |
Tobacco poisoning | 51.30 | 12.12 | 11 | 21295 | 105 | 64477321 |
Dependence | 50.79 | 12.12 | 21 | 21285 | 2134 | 64475292 |
Application site rash | 45.92 | 12.12 | 19 | 21287 | 1935 | 64475491 |
Chronic obstructive pulmonary disease | 44.13 | 12.12 | 82 | 21224 | 70966 | 64406460 |
Premature delivery | 43.01 | 12.12 | 41 | 21265 | 18548 | 64458878 |
Alcohol interaction | 41.98 | 12.12 | 23 | 21283 | 4378 | 64473048 |
Rheumatoid arthritis | 39.90 | 12.12 | 4 | 21302 | 164290 | 64313136 |
Application site irritation | 39.33 | 12.12 | 16 | 21290 | 1560 | 64475866 |
Rib deformity | 39.29 | 12.12 | 9 | 21297 | 119 | 64477307 |
Off label use | 37.86 | 12.12 | 97 | 21209 | 632709 | 63844717 |
Tobacco abuse | 37.35 | 12.12 | 13 | 21293 | 823 | 64476603 |
Anxiety | 37.32 | 12.12 | 149 | 21157 | 202500 | 64274926 |
Application site pain | 37.23 | 12.12 | 21 | 21285 | 4227 | 64473199 |
Withdrawal syndrome | 36.71 | 12.12 | 42 | 21264 | 23450 | 64453976 |
Application site scar | 35.62 | 12.12 | 9 | 21297 | 184 | 64477242 |
Drug use disorder | 35.19 | 12.12 | 23 | 21283 | 6031 | 64471395 |
Drug screen positive | 33.87 | 12.12 | 22 | 21284 | 5707 | 64471719 |
Treatment noncompliance | 33.25 | 12.12 | 55 | 21251 | 43427 | 64433999 |
Drug withdrawal syndrome | 33.04 | 12.12 | 46 | 21260 | 31245 | 64446181 |
Drug intolerance | 32.12 | 12.12 | 11 | 21295 | 187981 | 64289445 |
Loss of consciousness | 31.35 | 12.12 | 114 | 21192 | 148251 | 64329175 |
Euphoric mood | 31.07 | 12.12 | 22 | 21284 | 6569 | 64470857 |
Drug ineffective | 30.88 | 12.12 | 158 | 21148 | 840089 | 63637337 |
Reversible cerebral vasoconstriction syndrome | 30.25 | 12.12 | 15 | 21291 | 2327 | 64475099 |
Schizoaffective disorder | 29.27 | 12.12 | 13 | 21293 | 1574 | 64475852 |
Schizophrenia | 28.47 | 12.12 | 26 | 21280 | 11142 | 64466284 |
Maternal exposure during pregnancy | 27.74 | 12.12 | 82 | 21224 | 95802 | 64381624 |
Body temperature abnormal | 26.02 | 12.12 | 12 | 21294 | 1586 | 64475840 |
Tachycardia | 25.94 | 12.12 | 108 | 21198 | 149471 | 64327955 |
Maternal drugs affecting foetus | 25.86 | 12.12 | 12 | 21294 | 1608 | 64475818 |
Dysmetropsia | 25.81 | 12.12 | 6 | 21300 | 85 | 64477341 |
Therapeutic product effect decreased | 25.12 | 12.12 | 4 | 21302 | 115347 | 64362079 |
Application site vesicles | 24.93 | 12.12 | 11 | 21295 | 1311 | 64476115 |
Throat clearing | 24.80 | 12.12 | 11 | 21295 | 1327 | 64476099 |
Application site urticaria | 24.39 | 12.12 | 7 | 21299 | 235 | 64477191 |
Exposure during pregnancy | 23.98 | 12.12 | 68 | 21238 | 77607 | 64399819 |
Nightmare | 23.88 | 12.12 | 32 | 21274 | 20961 | 64456465 |
Regurgitation | 22.86 | 12.12 | 12 | 21294 | 2097 | 64475329 |
Emphysema | 21.72 | 12.12 | 25 | 21281 | 14044 | 64463382 |
Alopecia | 21.68 | 12.12 | 14 | 21292 | 165676 | 64311750 |
Unresponsive to stimuli | 21.66 | 12.12 | 50 | 21256 | 50343 | 64427083 |
Application site dermatitis | 21.58 | 12.12 | 6 | 21300 | 179 | 64477247 |
Mental status changes | 21.33 | 12.12 | 56 | 21250 | 61106 | 64416320 |
Renal impairment | 21.23 | 12.12 | 9 | 21297 | 135008 | 64342418 |
Infective exacerbation of chronic obstructive airways disease | 21.23 | 12.12 | 12 | 21294 | 2426 | 64475000 |
Loss of proprioception | 20.79 | 12.12 | 8 | 21298 | 674 | 64476752 |
Vitamin B12 deficiency | 20.70 | 12.12 | 16 | 21290 | 5456 | 64471970 |
Application site discolouration | 20.36 | 12.12 | 8 | 21298 | 712 | 64476714 |
Diarrhoea | 20.16 | 12.12 | 148 | 21158 | 722556 | 63754870 |
Reversible airways obstruction | 19.96 | 12.12 | 9 | 21297 | 1129 | 64476297 |
Arteriosclerosis coronary artery | 19.74 | 12.12 | 25 | 21281 | 15504 | 64461922 |
Pulmonary oedema | 19.70 | 12.12 | 64 | 21242 | 78610 | 64398816 |
Axonal neuropathy | 19.40 | 12.12 | 10 | 21296 | 1682 | 64475744 |
Arthropathy | 19.12 | 12.12 | 8 | 21298 | 120959 | 64356467 |
Oropharyngeal discomfort | 18.89 | 12.12 | 15 | 21291 | 5320 | 64472106 |
Oophoritis | 18.77 | 12.12 | 4 | 21302 | 37 | 64477389 |
Tobacco withdrawal symptoms | 18.51 | 12.12 | 3 | 21303 | 4 | 64477422 |
Nasal obstruction | 18.43 | 12.12 | 9 | 21297 | 1350 | 64476076 |
Joint swelling | 18.03 | 12.12 | 27 | 21279 | 215355 | 64262071 |
Arthralgia | 18.02 | 12.12 | 80 | 21226 | 442180 | 64035246 |
Fatigue | 17.82 | 12.12 | 160 | 21146 | 748570 | 63728856 |
Application site swelling | 17.69 | 12.12 | 7 | 21299 | 635 | 64476791 |
Derealisation | 17.62 | 12.12 | 9 | 21297 | 1486 | 64475940 |
Disease progression | 17.18 | 12.12 | 13 | 21293 | 141667 | 64335759 |
Palpitations | 16.99 | 12.12 | 74 | 21232 | 104414 | 64373012 |
Nervousness | 16.97 | 12.12 | 33 | 21273 | 29523 | 64447903 |
Tobacco interaction | 16.87 | 12.12 | 4 | 21302 | 62 | 64477364 |
Breathing-related sleep disorder | 16.65 | 12.12 | 5 | 21301 | 197 | 64477229 |
Chest pain | 16.62 | 12.12 | 134 | 21172 | 235846 | 64241580 |
Xanthogranuloma | 16.58 | 12.12 | 4 | 21302 | 67 | 64477359 |
Suicidal ideation | 16.54 | 12.12 | 54 | 21252 | 66488 | 64410938 |
Hepatocellular injury | 16.37 | 12.12 | 42 | 21264 | 45193 | 64432233 |
Foetal distress syndrome | 16.31 | 12.12 | 6 | 21300 | 446 | 64476980 |
False positive investigation result | 16.19 | 12.12 | 7 | 21299 | 794 | 64476632 |
Poor quality product administered | 15.78 | 12.12 | 11 | 21295 | 3204 | 64474222 |
Potentiating drug interaction | 15.71 | 12.12 | 16 | 21290 | 7836 | 64469590 |
Cardiac death | 15.67 | 12.12 | 8 | 21298 | 1320 | 64476106 |
Infection | 15.65 | 12.12 | 23 | 21283 | 184857 | 64292569 |
Intentional overdose | 15.63 | 12.12 | 65 | 21241 | 89879 | 64387547 |
Irritability | 15.29 | 12.12 | 36 | 21270 | 36710 | 64440716 |
Pain | 14.63 | 12.12 | 115 | 21191 | 553396 | 63924030 |
Abortion induced | 14.61 | 12.12 | 14 | 21292 | 6374 | 64471052 |
Mental disorder | 14.54 | 12.12 | 29 | 21277 | 26416 | 64451010 |
Accidental death | 14.33 | 12.12 | 11 | 21295 | 3714 | 64473712 |
Premature labour | 14.30 | 12.12 | 15 | 21291 | 7605 | 64469821 |
Myoclonic epilepsy | 14.23 | 12.12 | 8 | 21298 | 1600 | 64475826 |
Depression | 13.96 | 12.12 | 106 | 21200 | 183185 | 64294241 |
Premature separation of placenta | 13.81 | 12.12 | 7 | 21299 | 1137 | 64476289 |
Plethysmography | 13.60 | 12.12 | 3 | 21303 | 33 | 64477393 |
Non-small cell lung cancer stage IIIB | 13.52 | 12.12 | 3 | 21303 | 34 | 64477392 |
Psychotic disorder | 13.44 | 12.12 | 33 | 21273 | 34545 | 64442881 |
Sputum purulent | 13.36 | 12.12 | 7 | 21299 | 1219 | 64476207 |
Nasopharyngitis | 13.32 | 12.12 | 28 | 21278 | 196045 | 64281381 |
Full blood count abnormal | 13.31 | 12.12 | 30 | 21276 | 29727 | 64447699 |
Hypoxia | 13.25 | 12.12 | 61 | 21245 | 88088 | 64389338 |
Pre-eclampsia | 13.02 | 12.12 | 13 | 21293 | 6218 | 64471208 |
Application site warmth | 12.79 | 12.12 | 4 | 21302 | 181 | 64477245 |
Neuropathy peripheral | 12.75 | 12.12 | 12 | 21294 | 117513 | 64359913 |
Ischaemic stroke | 12.69 | 12.12 | 29 | 21277 | 29006 | 64448420 |
Pyrexia | 12.56 | 12.12 | 121 | 21185 | 558523 | 63918903 |
Gastrointestinal disorder | 12.55 | 12.12 | 7 | 21299 | 89702 | 64387724 |
Systemic lupus erythematosus | 12.48 | 12.12 | 5 | 21301 | 77607 | 64399819 |
Injection site erythema | 12.33 | 12.12 | 4 | 21302 | 70796 | 64406630 |
Hallucination, synaesthetic | 12.29 | 12.12 | 3 | 21303 | 53 | 64477373 |
Anaphylactic reaction | 12.22 | 12.12 | 50 | 21256 | 68614 | 64408812 |
Oedema mouth | 12.20 | 12.12 | 9 | 21297 | 2864 | 64474562 |
None
Source | Code | Description |
---|---|---|
ATC | N07BA01 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS DRUGS USED IN ADDICTIVE DISORDERS Drugs used in nicotine dependence |
FDA CS | M0014836 | Nicotine |
MeSH PA | D018678 | Cholinergic Agents |
MeSH PA | D018679 | Cholinergic Agonists |
MeSH PA | D005731 | Ganglionic Stimulants |
MeSH PA | D018377 | Neurotransmitter Agents |
MeSH PA | D018722 | Nicotinic Agonists |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D000077444 | Smoking Cessation Agents |
FDA EPC | N0000175706 | Cholinergic Nicotinic Agonist |
CHEBI has role | CHEBI:22917 | botanical insecticides |
CHEBI has role | CHEBI:35471 | psychotropic drugs |
CHEBI has role | CHEBI:35474 | anti-anxiety agents |
CHEBI has role | CHEBI:35703 | Xenobiotic |
CHEBI has role | CHEBI:47958 | muscarinic agonists |
CHEBI has role | CHEBI:49110 | peripheral nervous system drugs |
CHEBI has role | CHEBI:50846 | Immunologic factor |
CHEBI has role | CHEBI:50905 | teratogeno |
CHEBI has role | CHEBI:50910 | agente neurotoxico |
CHEBI has role | CHEBI:52290 | mitogens |
CHEBI has role | CHEBI:59163 | biological marker |
CHEBI has role | CHEBI:76924 | plant metabolites |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Nicotine dependence | indication | 56294008 | DOID:0050742 |
Smoking cessation assistance | indication | 384742004 | |
Pellagra | indication | 418186002 | DOID:8457 |
Niacin deficiency | indication | 418279001 | |
Nicotine Withdrawal Symptoms | indication | ||
Hyperlipidemia | off-label use | 55822004 | DOID:1168 |
Hypophosphatemia | contraindication | 4996001 | |
Alcoholism | contraindication | 7200002 | |
Peptic ulcer | contraindication | 13200003 | DOID:750 |
Esophagitis | contraindication | 16761005 | DOID:11963 |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Temporomandibular joint disorder | contraindication | 41888000 | |
Low blood pressure | contraindication | 45007003 | |
Diabetes mellitus type 1 | contraindication | 46635009 | DOID:9744 |
Thromboangiitis obliterans | contraindication | 52403007 | DOID:12918 |
Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Prinzmetal angina | contraindication | 87343002 | |
Gout | contraindication | 90560007 | DOID:13189 |
Magnetic resonance imaging | contraindication | 113091000 | |
Liver function tests abnormal | contraindication | 166603001 | |
Angina pectoris | contraindication | 194828000 | |
Arterial hemorrhage | contraindication | 234003006 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Raynaud's phenomenon | contraindication | 266261006 | |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Pheochromocytoma | contraindication | 302835009 | |
Acute coronary syndrome | contraindication | 394659003 | |
Pharyngitis | contraindication | 405737000 | DOID:2275 |
Disorder of coronary artery | contraindication | 414024009 | |
Myocardial infarction in recovery phase | contraindication | 418044006 | |
Hypertensive urgency | contraindication | 443482000 | |
Life-Threatening Cardiac Arrhythmias | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.05 | Basic |
pKa2 | 3.14 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | AGONIST | Ki | 8.56 | WOMBAT-PK | CHEMBL | |||
Neuronal acetylcholine receptor subunit alpha-7 | Ion channel | Ki | 5.39 | WOMBAT-PK | |||||
Potassium voltage-gated channel subfamily D member 3 | Ion channel | IC50 | 7.40 | WOMBAT-PK | |||||
Transient receptor potential cation channel subfamily A member 1 | Ion channel | ACTIVATOR | EC50 | 4.80 | IUPHAR | ||||
Neuronal acetylcholine receptor; alpha2/beta4 | Ion channel | Ki | 7.15 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha2/beta2 | Ion channel | Ki | 8.26 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha3/beta4 | Ion channel | Ki | 5.95 | WOMBAT-PK | |||||
Neuronal acetylcholine receptor; alpha3/beta2 | Ion channel | Ki | 7.85 | WOMBAT-PK | |||||
Neuronal acetylcholine receptor; alpha4/beta4 | Ion channel | Ki | 7.64 | CHEMBL | |||||
Serotonin 3 (5-HT3) receptor | Ion channel | Ki | 4.15 | CHEMBL | |||||
Acetylcholine receptor; alpha1/beta1/delta/gamma | Ion channel | Ki | 5.83 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3 | Ion channel | IC50 | 7.07 | CHEMBL | |||||
Acetylcholine receptor subunit alpha | Ion channel | IC50 | 4.68 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-3 | Ion channel | IC50 | 7.35 | CHEMBL | |||||
Cytochrome P450 2A6 | Enzyme | IC50 | 5.36 | WOMBAT-PK | |||||
Acetylcholine-binding protein | Unclassified | Ki | 7.20 | CHEMBL | |||||
Acetylcholine receptor subunit delta | Ion channel | Ki | 9 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-4 | Ion channel | Ki | 9.03 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-7 | Ion channel | Ki | 6.89 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-7 | Ion channel | Ki | 6.61 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-9 | Ion channel | Kd | 8.30 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit beta-4 | Ion channel | Ki | 7.14 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-3 | Ion channel | Ki | 7.33 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-2 | Ion channel | Ki | 7.92 | CHEMBL | |||||
Soluble acetylcholine receptor | Unclassified | Ki | 7.52 | CHEMBL | |||||
Acetylcholine receptor subunit alpha | Ion channel | IC50 | 4.64 | CHEMBL | |||||
Lycopene cyclase | Enzyme | IC50 | 5.32 | CHEMBL | |||||
Nicotinic acetylcholine receptor alpha 5 subunit | Ion channel | Ki | 5.61 | CHEMBL | |||||
Acetylcholine receptor subunit beta-like 2 | Ion channel | Ki | 5.57 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-4 | Ion channel | Ki | 8.72 | CHEMBL | |||||
Neuronal acetylcholine receptor subunit alpha-4 | Ion channel | IC50 | 8.15 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha2/beta2 | Ion channel | Ki | 8.26 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha3/beta2 | Ion channel | Ki | 9 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha3/beta4 | Ion channel | Ki | 6.70 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | Kd | 9.40 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha4/beta4 | Ion channel | Ki | 8.26 | CHEMBL | |||||
Neuronal acetylcholine receptor | Ion channel | Kd | 11 | CHEMBL | |||||
Neuronal acetylcholine receptor; alpha2/beta4 | Ion channel | Ki | 7.15 | CHEMBL | |||||
Acetylcholine receptor | Ion channel | Ki | 5.20 | CHEMBL | |||||
Muscarinic acetylcholine receptor | GPCR | IC50 | 4.55 | CHEMBL | |||||
Transient receptor potential cation channel subfamily A member 1 | Ion channel | EC50 | 5 | CHEMBL | |||||
Potassium voltage-gated channel subfamily D member 3 | Ion channel | BLOCKER | IC50 | 7.40 | IUPHAR |
ID | Source |
---|---|
4020286 | VUID |
N0000148163 | NUI |
D03365 | KEGG_DRUG |
65-31-6 | SECONDARY_CAS_RN |
4018610 | VANDF |
4020286 | VANDF |
C0028040 | UMLSCUI |
CHEBI:17688 | CHEBI |
NCT | PDB_CHEM_ID |
CHEMBL3 | ChEMBL_ID |
DB00184 | DRUGBANK_ID |
D009538 | MESH_DESCRIPTOR_UI |
89594 | PUBCHEM_CID |
2585 | IUPHAR_LIGAND_ID |
6M3C89ZY6R | UNII |
1306106 | RXNORM |
11529 | MMSL |
5173 | MMSL |
5174 | MMSL |
72003 | MMSL |
d00316 | MMSL |
001770 | NDDF |
003575 | NDDF |
323283001 | SNOMEDCT_US |
68540007 | SNOMEDCT_US |
77544001 | SNOMEDCT_US |
D061485 | MESH_DESCRIPTOR_UI |
CHEMBL1201536 | ChEMBL_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Nicotrol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-5400 | INHALANT | 4 mg | RESPIRATORY (INHALATION) | NDA | 29 sections |
Nicotrol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-5401 | SPRAY, METERED | 10 mg | NASAL | NDA | 28 sections |
Nicotrol | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0009-5401 | SPRAY, METERED | 10 mg | NASAL | NDA | 28 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0029 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0053 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0170 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
good sense nicotinemint | HUMAN OTC DRUG LABEL | 1 | 0113-0206 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0344 | LOZENGE | 2 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0422 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0456 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0532 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0704 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0713 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0734 | LOZENGE | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0749 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0761 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0854 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
good sense nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0873 | LOZENGE | 4 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-0957 | LOZENGE | 4 mg | ORAL | ANDA | 15 sections |
Good Sense Nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-1125 | LOZENGE | 2 mg | ORAL | ANDA | 15 sections |
good sense nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-1190 | LOZENGE | 4 mg | ORAL | ANDA | 15 sections |
good sense nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-1352 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7007 | LOZENGE | 4 mg | ORAL | ANDA | 14 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7008 | LOZENGE | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7029 | GUM, CHEWING | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7124 | LOZENGE | 2 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7170 | GUM, CHEWING | 4 mg | ORAL | ANDA | 15 sections |
basic care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7190 | LOZENGE | 4 mg | ORAL | ANDA | 15 sections |
Basic Care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7201 | LOZENGE | 2 mg | ORAL | ANDA | 14 sections |
Basic Care nicotine | HUMAN OTC DRUG LABEL | 1 | 0113-7203 | LOZENGE | 4 mg | ORAL | ANDA | 14 sections |